Certain Adalimumab, Processes for Manufacturing or Relating to Same, and Products Containing Same; Notice of Institution of Investigation, 4912-4913 [2022-01917]
Download as PDF
<![CDATA[
4912
Federal Register / Vol. 87, No. 20 / Monday, January 31, 2022 / Notices
terminating the lease or rescinding
approval of the Tribal regulations and
reassuming lease approval
responsibilities. Moreover, the Secretary
continues to review, approve, and
monitor individual Indian land leases
and other types of leases not covered
under the Tribal regulations according
to the Part 162 regulations.
Accordingly, the Federal and Tribal
interests weigh heavily in favor of
preemption of State and local taxes on
lease-related activities and interests,
regardless of whether the lease is
governed by Tribal leasing regulations
or Part 162. Improvements, activities,
and leasehold or possessory interests
may be subject to taxation by the Tule
River Indian Tribe of the Tule River
Reservation, California.
Bryan Newland,
Assistant Secretary—Indian Affairs.
[FR Doc. 2022–01877 Filed 1–28–22; 8:45 am]
BILLING CODE 4337–15–P
INTERNATIONAL TRADE
COMMISSION
[Investigation No. 337–TA–1296]
Certain Adalimumab, Processes for
Manufacturing or Relating to Same,
and Products Containing Same; Notice
of Institution of Investigation
U.S. International Trade
Commission.
ACTION: Notice.
AGENCY:
Notice is hereby given that a
complaint was filed with the U.S.
International Trade Commission on
December 17, 2021, under section 337 of
the Tariff Act of 1930, as amended, on
behalf of AbbVie Inc. of Chicago,
Illinois; AbbVie Biotechnology Ltd. of
Bermuda; and AbbVie Operations
Singapore Pte. Ltd. of Singapore. A
supplement to the complaint was filed
on January 4, 2022. The complaint, as
supplemented, alleges violations of
section 337 based upon the importation
into the United States and the sale of
certain adalimumab, processes for
manufacturing or relating to same, and
products containing same by reason of
the misappropriation of trade secrets
and tortious interference with
contractual relations, the threat or effect
of which is to destroy or substantially
injure an industry in the United States.
The complainant requests that the
Commission institute an investigation
and, after the investigation, issue a
limited exclusion order and cease and
desist orders.
ADDRESSES: The complaint, except for
any confidential information contained
khammond on DSKJM1Z7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:38 Jan 28, 2022
Jkt 256001
therein, may be viewed on the
Commission’s electronic docket (EDIS)
at https://edis.usitc.gov. For help
accessing EDIS, please email
EDIS3Help@usitc.gov. Hearing impaired
individuals are advised that information
on this matter can be obtained by
contacting the Commission’s TDD
terminal on (202) 205–1810. Persons
with mobility impairments who will
need special assistance in gaining access
to the Commission should contact the
Office of the Secretary at (202) 205–
2000. General information concerning
the Commission may also be obtained
by accessing its internet server at
https://www.usitc.gov.
FOR FURTHER INFORMATION CONTACT:
Pathenia M. Proctor, The Office of
Unfair Import Investigations, U.S.
International Trade Commission,
telephone (202) 205–2560.
SUPPLEMENTARY INFORMATION:
Authority: The authority for
institution of this investigation is
contained in section 337 of the Tariff
Act of 1930, as amended, 19 U.S.C.
1337, and in section 210.10 of the
Commission’s Rules of Practice and
Procedure, 19 CFR 210.10 (2021).
Scope of Investigation: Having
considered the complaint, the U.S.
International Trade Commission, on
January 25, 2022, Ordered that—
(1) Pursuant to subsection (b) of
section 337 of the Tariff Act of 1930, as
amended, an investigation be instituted
to determine whether there is a
violation of subsection (a)(1)(A) of
section 337 in the importation into the
United States or in the sale of certain
products identified in paragraph (2) by
reason of the misappropriation of trade
secrets and tortious interference with
contractual relations, the threat or effect
of which is to destroy or substantially
injure an industry in the United States;
(2) Pursuant to section 210.10(b)(1) of
the Commission’s Rules of Practice and
Procedure, 19 CFR 210.10(b)(1), the
plain language description of the
accused products or category of accused
products, which defines the scope of the
investigation, is ‘‘adalimumab (drug
substance and drug product), vials,
prefilled syringes, autoinjectors or other
presentations containing same, and the
methods of manufacturing and
processes for making the same’’;
(3) For the purpose of the
investigation so instituted, the following
are hereby named as parties upon which
this notice of investigation shall be
served:
(a) The complainants are:
AbbVie Inc., 1 North Waukegan Rd.,
North Chicago, IL 60064
PO 00000
Frm 00081
Fmt 4703
Sfmt 4703
AbbVie Biotechnology Ltd, Harbour
Fiduciary Services Limited, Thistle
House, 4 Burnaby Street, Hamilton
HM11, Bermuda
AbbVie Operations Singapore Pte. Ltd.,
23 Tuas South Avenue 6, Singapore
637022
(b) The respondents are the following
entities alleged to be in violation of
section 337, and are the parties upon
which the complaint is to be served:
Alvotech hf., S#mundargata 15–19, 101
Reykjavik, Iceland
Alvotech Germany GmbH, Karl-HeinzBeckurts-Str. 13, 52428, Ju¨lich,
Nordrhein-Westfalen, Germany
Alvotech Swiss AG, Thurgauerstrasse 54
Zu¨rich, 8050 Switzerland
Alvotech USA Inc., 1201 Wilson Blvd.,
Ste 2130, Arlington, VA, 22209
Ivers-Lee AG, Kirchbergstrasse 160,
Burgdorf, Bern, 3400 Switzerland
Teva Pharmaceutical Industries Ltd., 5
Basel Street, Petach Tikva, 49131
Israel
Teva Pharmaceuticals USA Inc., 1090
Horsham Road, North Wales, PA
19454
(c) The Office of Unfair Import
Investigations, U.S. International Trade
Commission, 500 E Street, SW, Suite
401, Washington, DC 20436; and
(4) For the investigation so instituted,
the Chief Administrative Law Judge,
U.S. International Trade Commission,
shall designate the presiding
Administrative Law Judge.
Responses to the complaint and the
notice of investigation must be
submitted by the named respondents in
accordance with section 210.13 of the
Commission’s Rules of Practice and
Procedure, 19 CFR 210.13. Pursuant to
19 CFR 201.16(e) and 210.13(a), as
amended in 85 FR 15798 (March 19,
2020), such responses will be
considered by the Commission if
received not later than 20 days after the
date of service by the complainants of
the complaint and the notice of
investigation. Extensions of time for
submitting responses to the complaint
and the notice of investigation will not
be granted unless good cause therefor is
shown.
Failure of a/the respondents to file a
timely response to each allegation in the
complaint and in this notice may be
deemed to constitute a waiver of the
right to appear and contest the
allegations of the complaint and this
notice, and to authorize the
administrative law judge and the
Commission, without further notice to
the respondent, to find the facts to be as
alleged in the complaint and this notice
and to enter an initial determination
and a final determination containing
E:\FR\FM\31JAN1.SGM
31JAN1
Federal Register / Vol. 87, No. 20 / Monday, January 31, 2022 / Notices
such findings, and may result in the
issuance of an exclusion order or a cease
and desist order or both directed against
the respondent.
By order of the Commission.
Issued: January 26, 2022.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2022–01917 Filed 1–28–22; 8:45 am]
BILLING CODE 7020–02–P
INTERNATIONAL TRADE
COMMISSION
[Investigation No. 337–TA–1294]
Certain High-Performance Gravity-Fed
Water Filters and Products Containing
the Same; Notice of Institution of
Investigation
International Trade
Commission.
ACTION: Notice.
AGENCY:
Notice is hereby given that a
complaint was filed with the U.S.
International Trade Commission on
December 27, 2021, under section 337 of
the Tariff Act of 1930, as amended, on
behalf of Brita LP of Switzerland. Letters
supplementing the complaint were filed
on January 10, 2022. The complaint
alleges violations of section 337 based
upon the importation into the United
States, the sale for importation, and the
sale within the United States after
importation of certain high-performance
gravity-fed water filters and products
containing the same by reason of
infringement of certain claims of U.S.
Patent No. 8,167,141 (‘‘the ’141 patent’’).
The complaint further alleges that an
industry in the United States exists as
required by the applicable Federal
Statute. The complainant requests that
the Commission institute an
investigation and, after the
investigation, issue a limited exclusion
order and cease and desist orders.
ADDRESSES: The complaint, except for
any confidential information contained
therein, may be viewed on the
Commission’s electronic docket (EDIS)
at https://edis.usitc.gov. For help
accessing EDIS, please email
EDIS3Help@usitc.gov. Hearing impaired
individuals are advised that information
on this matter can be obtained by
contacting the Commission’s TDD
terminal on (202) 205–1810. Persons
with mobility impairments who will
need special assistance in gaining access
to the Commission should contact the
Office of the Secretary at (202) 205–
2000. General information concerning
the Commission may also be obtained
khammond on DSKJM1Z7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:38 Jan 28, 2022
Jkt 256001
by accessing its internet server at
https://www.usitc.gov.
FOR FURTHER INFORMATION CONTACT:
Jessica Mullan, Office of Docket
Services, U.S. International Trade
Commission, telephone (202) 205–1802.
SUPPLEMENTARY INFORMATION:
Authority: The authority for
institution of this investigation is
contained in section 337 of the Tariff
Act of 1930, as amended, 19 U.S.C.
1337, and in section 210.10 of the
Commission’s Rules of Practice and
Procedure, 19 CFR 210.10 (2021).
Scope of Investigation: Having
considered the complaint, the U.S.
International Trade Commission, on
January 25, 2022, ordered that—
(1) Pursuant to subsection (b) of
section 337 of the Tariff Act of 1930, as
amended, an investigation be instituted
to determine whether there is a
violation of subsection (a)(1)(B) of
section 337 in the importation into the
United States, the sale for importation,
or the sale within the United States after
importation of certain products
identified in paragraph (2) by reason of
infringement of one or more of claims
1–6, 20–21, and 23–24 of the ’141
patent, and whether an industry in the
United States exists as required by
subsection (a)(2) of section 337;
(2) Pursuant to section 210.10(b)(1) of
the Commission’s Rules of Practice and
Procedure, 19 CFR 210.10(b)(1), the
plain language description of the
accused products or category of accused
products, which defines the scope of the
investigation, is ‘‘gravity-fed water
filters that meet a specified combination
of high-performance criteria relating to
filter rate and lead volume, lead
reduction, and lifetime usage, and water
container products that are sold with
such filters’’;
(3) For the purpose of the
investigation so instituted, the following
are hereby named as parties upon which
this notice of investigation shall be
served:
(a) The complainant is:
Brita LP, Faubourg du Lac 11, 2000
Neuchatel NE, Switzerland
(b) The respondents are the following
entities alleged to be in violation of
section 337, and are the parties upon
which the complaint is to be served:
EcoLife Technologies, Inc., 17910 Ajax
Cir, City of Industry, CA 91748
Qingdao Ecopure Filter Co., Ltd., No.
13, Yishengbai Road, Environmental
Protection Industry Zone, Jimo,
Qingdao, Shandong Province, 266201,
China
Kaz USA, Inc., 1 Helen of Troy Plaza,
El Paso, TX 79912–1150
PO 00000
Frm 00082
Fmt 4703
Sfmt 4703
4913
Helen of Troy Limited, 1 Helen of Troy
Plaza, El Paso, TX 79912–1150
Zero Technologies, LLC, 7 Neshaminy
Interplex, Suite 116, Trevose, PA
19053
Culligan International Co., 9399 W
Higgins Rd., Rosemont, IL 60018
Vestergaard Frandsen Inc., 333 W
Ostend St., Suite 300, Baltimore, MD
21230
Mavea LLC, 1800 Blakenship Road,
Suite 200, West Linn, OR 97068
Brita GmbH, Heinrich-Hertz-Str. 4,
65232 Taunusstein, Germany
(4) For the investigation so instituted,
the Chief Administrative Law Judge,
U.S. International Trade Commission,
shall designate the presiding
Administrative Law Judge.
The Office of Unfair Import
Investigations will not participate as a
party in this investigation.
Responses to the complaint and the
notice of investigation must be
submitted by the named respondents in
accordance with section 210.13 of the
Commission’s Rules of Practice and
Procedure, 19 CFR210.13. Pursuant to
19 CFR 201.16(e) and 210.13(a), as
amended in 85 FR 15798 (March 19,
2020), such responses will be
considered by the Commission if
received not later than 20 days after the
date of service by the complainant of the
complaint and the notice of
investigation. Extensions of time for
submitting responses to the complaint
and the notice of investigation will not
be granted unless good cause therefor is
shown.
Failure of a respondent to file a timely
response to each allegation in the
complaint and in this notice may be
deemed to constitute a waiver of the
right to appear and contest the
allegations of the complaint and this
notice, and to authorize the
administrative law judge and the
Commission, without further notice to
the respondent, to find the facts to be as
alleged in the complaint and this notice
and to enter an initial determination
and a final determination containing
such findings, and may result in the
issuance of an exclusion order or a cease
and desist order or both directed against
the respondent.
By order of the Commission.
Issued: January 25, 2022.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2022–01850 Filed 1–28–22; 8:45 am]
BILLING CODE 7020–02–P
E:\FR\FM\31JAN1.SGM
31JAN1
]]>Agencies
[Federal Register Volume 87, Number 20 (Monday, January 31, 2022)]
[Notices]
[Pages 4912-4913]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-01917]
=======================================================================
-----------------------------------------------------------------------
INTERNATIONAL TRADE COMMISSION
[Investigation No. 337-TA-1296]
Certain Adalimumab, Processes for Manufacturing or Relating to
Same, and Products Containing Same; Notice of Institution of
Investigation
AGENCY: U.S. International Trade Commission.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that a complaint was filed with the
U.S. International Trade Commission on December 17, 2021, under section
337 of the Tariff Act of 1930, as amended, on behalf of AbbVie Inc. of
Chicago, Illinois; AbbVie Biotechnology Ltd. of Bermuda; and AbbVie
Operations Singapore Pte. Ltd. of Singapore. A supplement to the
complaint was filed on January 4, 2022. The complaint, as supplemented,
alleges violations of section 337 based upon the importation into the
United States and the sale of certain adalimumab, processes for
manufacturing or relating to same, and products containing same by
reason of the misappropriation of trade secrets and tortious
interference with contractual relations, the threat or effect of which
is to destroy or substantially injure an industry in the United States.
The complainant requests that the Commission institute an investigation
and, after the investigation, issue a limited exclusion order and cease
and desist orders.
ADDRESSES: The complaint, except for any confidential information
contained therein, may be viewed on the Commission's electronic docket
(EDIS) at https://edis.usitc.gov. For help accessing EDIS, please email
[email protected]. Hearing impaired individuals are advised that
information on this matter can be obtained by contacting the
Commission's TDD terminal on (202) 205-1810. Persons with mobility
impairments who will need special assistance in gaining access to the
Commission should contact the Office of the Secretary at (202) 205-
2000. General information concerning the Commission may also be
obtained by accessing its internet server at https://www.usitc.gov.
FOR FURTHER INFORMATION CONTACT: Pathenia M. Proctor, The Office of
Unfair Import Investigations, U.S. International Trade Commission,
telephone (202) 205-2560.
SUPPLEMENTARY INFORMATION:
Authority: The authority for institution of this investigation is
contained in section 337 of the Tariff Act of 1930, as amended, 19
U.S.C. 1337, and in section 210.10 of the Commission's Rules of
Practice and Procedure, 19 CFR 210.10 (2021).
Scope of Investigation: Having considered the complaint, the U.S.
International Trade Commission, on January 25, 2022, Ordered that--
(1) Pursuant to subsection (b) of section 337 of the Tariff Act of
1930, as amended, an investigation be instituted to determine whether
there is a violation of subsection (a)(1)(A) of section 337 in the
importation into the United States or in the sale of certain products
identified in paragraph (2) by reason of the misappropriation of trade
secrets and tortious interference with contractual relations, the
threat or effect of which is to destroy or substantially injure an
industry in the United States;
(2) Pursuant to section 210.10(b)(1) of the Commission's Rules of
Practice and Procedure, 19 CFR 210.10(b)(1), the plain language
description of the accused products or category of accused products,
which defines the scope of the investigation, is ``adalimumab (drug
substance and drug product), vials, prefilled syringes, autoinjectors
or other presentations containing same, and the methods of
manufacturing and processes for making the same'';
(3) For the purpose of the investigation so instituted, the
following are hereby named as parties upon which this notice of
investigation shall be served:
(a) The complainants are:
AbbVie Inc., 1 North Waukegan Rd., North Chicago, IL 60064
AbbVie Biotechnology Ltd, Harbour Fiduciary Services Limited, Thistle
House, 4 Burnaby Street, Hamilton HM11, Bermuda
AbbVie Operations Singapore Pte. Ltd., 23 Tuas South Avenue 6,
Singapore 637022
(b) The respondents are the following entities alleged to be in
violation of section 337, and are the parties upon which the complaint
is to be served:
Alvotech hf., S[aelig]mundargata 15-19, 101 Reykjavik, Iceland
Alvotech Germany GmbH, Karl-Heinz-Beckurts-Str. 13, 52428, J[uuml]lich,
Nordrhein-Westfalen, Germany
Alvotech Swiss AG, Thurgauerstrasse 54 Z[uuml]rich, 8050 Switzerland
Alvotech USA Inc., 1201 Wilson Blvd., Ste 2130, Arlington, VA, 22209
Ivers-Lee AG, Kirchbergstrasse 160, Burgdorf, Bern, 3400 Switzerland
Teva Pharmaceutical Industries Ltd., 5 Basel Street, Petach Tikva,
49131 Israel
Teva Pharmaceuticals USA Inc., 1090 Horsham Road, North Wales, PA 19454
(c) The Office of Unfair Import Investigations, U.S. International
Trade Commission, 500 E Street, SW, Suite 401, Washington, DC 20436;
and
(4) For the investigation so instituted, the Chief Administrative
Law Judge, U.S. International Trade Commission, shall designate the
presiding Administrative Law Judge.
Responses to the complaint and the notice of investigation must be
submitted by the named respondents in accordance with section 210.13 of
the Commission's Rules of Practice and Procedure, 19 CFR 210.13.
Pursuant to 19 CFR 201.16(e) and 210.13(a), as amended in 85 FR 15798
(March 19, 2020), such responses will be considered by the Commission
if received not later than 20 days after the date of service by the
complainants of the complaint and the notice of investigation.
Extensions of time for submitting responses to the complaint and the
notice of investigation will not be granted unless good cause therefor
is shown.
Failure of a/the respondents to file a timely response to each
allegation in the complaint and in this notice may be deemed to
constitute a waiver of the right to appear and contest the allegations
of the complaint and this notice, and to authorize the administrative
law judge and the Commission, without further notice to the respondent,
to find the facts to be as alleged in the complaint and this notice and
to enter an initial determination and a final determination containing
[[Page 4913]]
such findings, and may result in the issuance of an exclusion order or
a cease and desist order or both directed against the respondent.
By order of the Commission.
Issued: January 26, 2022.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2022-01917 Filed 1-28-22; 8:45 am]
BILLING CODE 7020-02-P
